Generic Firms Want Congress To Build On CARES Act To Prevent Critical Drug Shortages
The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.
You may also be interested in...
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.
As costs and delays mount, the brand and generic groups seek government solutions. AAM continues to press for federal contracts, and PhRMA wants the Department of Transportation to use its enforcement discretion under CARES Act to mandate international flights. AAM survey finds pandemic has caused 224% spike in the cost of transporting drugs.